Table 1

Antibody classification according to structure, with examples of products that are licensed or under development

mAb category

Suffix

Examples

Specificity

Reference


Chimeric

-ximab

Infliximab (Remicade®)

TNF-α

[59]

Rituximab (Rituxan®, Mabthera®)

CD20

[60]

Humanised

-zumab

Alemtuzumab (MabCampath®)

CD52

[18]

Tocilizumab (RoActemra®)

IL-6R

[61]

Ocrelizumab

CD20

[62]

Epratuzumab

CD22

[63]

Certolizumab pegol (PEGylated Fab fragment) (Cimzia®)

TNF-α

[64]

Otelixizumab (Aglycosyl)

CD3

[42]

Teplizumab (Fc-mutated)

CD3

[65]

Visilizumab (Fc-mutated)

CD3

[44]

'Fully human'

-mumab

Adalimumab (Humira®)

TNF-α

[66]

Ofatumumab (Humax-CD20®)

CD20

[67]

Belimumab (LymphoStat-B®)

BLyS

[68]

Golimumab

TNF-α

[69]

Fusion proteins

-cept

Etanercept (Enbrel®)

TNF-α

[70]

Abatacept (Orencia®)

CD80/CD86

[71]

Atacicept

BLyS/BAFF

[72]


BAFF, B-cell activating factor; BLyS, B-lymphocyte stimulator; Fab, fragment antigen-binding; Fc, fragment crystallisable; mAb, monoclonal antibody; TNF-α, tumour necrosis factor-alpha.

Isaacs Arthritis Research & Therapy 2009 11:225   doi:10.1186/ar2594